

May 13, 2020



# Capricor Therapeutics to Present First Quarter 2020 Financial Results and Recent Corporate Update on May 14

**Company to Host Conference Call, May 14, 2020, at 4:30 p.m. ET**

LOS ANGELES, May 13, 2020 (GLOBE NEWSWIRE) -- [Capricor Therapeutics](#) ("Capricor") (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, today announced that it will release its financial results for the first quarter ended March 31, 2020, after the market close on Thursday, May 14, 2020. Company management will host a conference call and webcast with slides to discuss its financial results and provide a general business update at 4:30 p.m. (ET) on the same day.

**Title:** Capricor Therapeutics First Quarter 2020 Financial Results and Recent Corporate Update Conference Call and Webcast

**Date:** Thursday, May 14, 2020

**Time:** 4:30 p.m. ET

**Conference** Toll-Free: 800-734-8507

**Call Details:** International: 212-231-2932  
Conference ID: 21962261

**Webcast:** <http://public.viavid.com/index.php?id=139834>

## About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment and prevention of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. For more information, [visit www.capricor.com](http://www.capricor.com) and follow the Company on [Facebook](#), [Instagram](#) and [Twitter](#).

## Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market;

plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on March 27, 2020. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

*CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor's exosome-based candidates have been approved for clinical investigation.*

**For more information, please contact:**

**Media Contact:**

Caitlin Kasunich  
KCSA Strategic Communications  
[ckasunich@kcsa.com](mailto:ckasunich@kcsa.com)  
212.896.1241

**Investor Contact:**

Joyce Allaire  
LifeSci Advisors, LLC  
[jallaire@lifesciadvisors.com](mailto:jallaire@lifesciadvisors.com)  
617.435.6602

**Company Contact:**

AJ Bergmann, Chief Financial Officer  
[abergmann@capricor.com](mailto:abergmann@capricor.com)  
310.358.3200



Source: Capricor Therapeutics